CL2020002671A1 - Sales de meglumina de tienopirimidinas - Google Patents

Sales de meglumina de tienopirimidinas

Info

Publication number
CL2020002671A1
CL2020002671A1 CL2020002671A CL2020002671A CL2020002671A1 CL 2020002671 A1 CL2020002671 A1 CL 2020002671A1 CL 2020002671 A CL2020002671 A CL 2020002671A CL 2020002671 A CL2020002671 A CL 2020002671A CL 2020002671 A1 CL2020002671 A1 CL 2020002671A1
Authority
CL
Chile
Prior art keywords
thienopyrimidines
meglumine salts
meglumine
salts
thienopyrimidine
Prior art date
Application number
CL2020002671A
Other languages
English (en)
Inventor
Anuj K Kumar
Raymond E Forslund
Original Assignee
Cardurion Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardurion Pharmaceuticals Llc filed Critical Cardurion Pharmaceuticals Llc
Publication of CL2020002671A1 publication Critical patent/CL2020002671A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

En la presente se divulgan las sales de meglumina de tienopirimidina según la fórmula (I) utilizada para tratar o prevenir la insuficiencia cardiaca.
CL2020002671A 2018-04-17 2020-10-15 Sales de meglumina de tienopirimidinas CL2020002671A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862658683P 2018-04-17 2018-04-17

Publications (1)

Publication Number Publication Date
CL2020002671A1 true CL2020002671A1 (es) 2021-04-16

Family

ID=68161061

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002671A CL2020002671A1 (es) 2018-04-17 2020-10-15 Sales de meglumina de tienopirimidinas

Country Status (16)

Country Link
US (2) US10822346B2 (es)
EP (1) EP3781155A4 (es)
JP (1) JP2021522186A (es)
KR (1) KR20210002541A (es)
CN (1) CN112367989A (es)
AU (1) AU2019255233A1 (es)
BR (1) BR112020021153A2 (es)
CA (1) CA3097384A1 (es)
CL (1) CL2020002671A1 (es)
CO (1) CO2020014069A2 (es)
IL (1) IL278064A (es)
MX (1) MX2020010884A (es)
PE (1) PE20211480A1 (es)
PH (1) PH12020551701A1 (es)
SG (1) SG11202010161UA (es)
WO (1) WO2019204298A1 (es)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4377583A (en) 1981-08-21 1983-03-22 Mead Johnson & Company N-Methyl-D-glucamine salt of with 3,4-dihydro-5-methyl-6-(2-methylpropyl)-4-oxothieno[2,3-d]pyrimidine-2-carboxylic acid
WO1989008113A1 (fr) * 1988-03-02 1989-09-08 Yoshitomi Pharmaceutical Industries, Ltd. COMPOSES DE 3,4-DIHYDROTHIENO[2,3-d]PYRIMIDINE ET LEURS APPLICATIONS PHARMACOLOGIQUES
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
EP1908765B1 (en) * 2005-06-14 2014-10-22 ASKA Pharmaceutical Co., Ltd. Thienopyrimidine derivative
EP2402347A1 (en) 2006-04-26 2012-01-04 F. Hoffmann-La Roche AG Pharmaceutical compounds
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
CN103038238B (zh) * 2010-05-31 2016-05-04 Aska制药株式会社 噻吩并嘧啶衍生物的结晶
WO2014110344A1 (en) * 2013-01-11 2014-07-17 Novartis Ag Meglumine salt forms of 2-((1 r,4r)-4-(4-(5-(benzoxazol-2-ylamino)pyridin-2-yl)phenyl)cyclohexyl) acetic acid and their use as dgat1 inhibitors
CA3030021A1 (en) * 2016-07-07 2018-01-11 Cardurion Pharmaceuticals, Llc Methods for treatment of heart failure

Also Published As

Publication number Publication date
PE20211480A1 (es) 2021-08-05
WO2019204298A1 (en) 2019-10-24
KR20210002541A (ko) 2021-01-08
IL278064A (en) 2020-11-30
EP3781155A1 (en) 2021-02-24
CO2020014069A2 (es) 2021-01-29
MX2020010884A (es) 2021-02-26
JP2021522186A (ja) 2021-08-30
SG11202010161UA (en) 2020-11-27
CA3097384A1 (en) 2019-10-24
PH12020551701A1 (en) 2021-09-06
CN112367989A (zh) 2021-02-12
US20190315765A1 (en) 2019-10-17
US20210139499A1 (en) 2021-05-13
AU2019255233A1 (en) 2020-11-26
BR112020021153A2 (pt) 2021-03-23
EP3781155A4 (en) 2021-10-06
US10822346B2 (en) 2020-11-03

Similar Documents

Publication Publication Date Title
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
CO2021005987A2 (es) Compuestos de anillo fusionado
CY1122712T1 (el) ΧΡΗΣΗ ΠΑΡΑΓΩΓΩΝ ΠΥΡΑΖΟΛΟΠΥΡΙΜΙΔΙΝΗΣ ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ ΣΧΕΤΙΚΩΝ ΜΕ PI3Kδ ΔΙΑΤΑΡΑΧΩΝ
CO2021003036A2 (es) Compuestos de anillo fusionado
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
CL2019001709A1 (es) Derivados pirazol como inhibidores de malt1.
BR112020008817B8 (pt) Compostos moduladores da via de estresse integrada
CL2017002606A1 (es) Inhibidor de bromodominio
CL2018002505A1 (es) Inhibidores del envejecimiento proteico-proteico wdr5
CU24603B1 (es) Imidazopirimidinas diazabicíclicas sustituidas útiles en el tratamiento de trastornos respiratorios
EA201990833A1 (ru) Соединение пиридина
CR20150571A (es) Compuestos y composiciones terapéuticos
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
UY36716A (es) Moduladores de receptores nucleares
EA202191519A1 (ru) Модуляторы trex1
UY35274A (es) Compuestos y métodos para tratar infecciones bacterianas
BR112021026668A2 (pt) Compostos heterocíclicos como inibidores de bet
EA201790800A1 (ru) Замещенные производные бензотиофенила в качестве агонистов gpr40 для лечения диабета ii типа
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
DOP2016000120A (es) Nuevos inhibidores de dgat2
CO2017010530A2 (es) Derivados de pirrolidincarboxamido y métodos para prepararlos y usarlos
CL2021000292A1 (es) Benzimidazoles sustituidos como inhibidores de pad4.
EA201691412A1 (ru) Гидроксиформамидные производные и их применение
CL2018001067A1 (es) Compuesto piranodipiridínico.